Bifunctional Pyridine Linker Enables Sequential, Stable Bioconjugation for ADCs and Peptides
- A programmable, bifunctional pyridine scaffold bearing a thianthrenium leaving group and a fluorine handle enables two sequential, chemoselective coupling reactions — first with alkylamines, then with cysteine thiols.
- The resulting aryl-cysteine linkage is non-chiral and stable, addressing limitations of existing bioconjugation approaches that often yield reversible linkages or stereochemical mixtures.
- Both coupling steps show high functional-group tolerance and chemoselectivity, making the chemistry compatible with complex peptides and proteins.
- The platform was applied to late-stage peptide diversification and stapling, as well as site-selective protein functionalization.
- Researchers also used the method to build an analog of the HER2-targeting antibody-drug conjugate MRG002 with a tunable drug-to-antibody ratio, reporting improved payload retention in serum relative to conventional linkage chemistry.
Maleimide-cysteine chemistry's dirty secret is retro-Michael instability — payload leaches back into circulation, and DAR isn't as fixed as the spec sheet claims. This bifunctional pyridine/thianthrenium scaffold attacks that head-on: the resulting aryl-thioether is non-chiral and hydrolytically stable, so no diastereomer mixtures and no slow linker exchange with serum thiols. Sequential chemoselectivity — amine coupling first, cysteine second, off one handle — is a real practical upgrade for installing orthogonal payloads/tags, not just another NHS-ester variant. What earns my attention is that they didn't stop at peptide-stapling demos: a tunable-DAR HER2 ADC analog of MRG002 with improved serum payload retention versus conventional linkage is the kind of proof point that actually moves a methodology from academic curiosity toward something worth piloting. Thianthrenium reagent scale-up and cost will decide if it ever displaces maleimide on a GMP line.